Search

Search Constraints

You searched for: Author/Creator Nishimura, Takashi

Search Results

1. A Novel SAVE Score to Stratify Decompensation Risk in Compensated Advanced Chronic Liver Disease (CHESS2102): An International Multicenter Cohort Study. (15th October 2022)

2. A phase 2 study of bevacizumab in combination with carboplatin and paclitaxel in patients with non-squamous non-small-cell lung cancer harboring mutations of epidermal growth factor receptor (EGFR) after failing first-line EGFR-tyrosine kinase inhibitors (HANSHIN Oncology Group 0109). Issue 2 (February 2015)

3. A phase 2 study of bevacizumab in combination with carboplatin and paclitaxel in patients with non-squamous non-small-cell lung cancer harboring mutations of epidermal growth factor receptor (EGFR) after failing first-line EGFR-tyrosine kinase inhibitors (HANSHIN Oncology Group 0109). Issue 2 (February 2015)

4. A phase II study of low starting dose of afatinib as first-line treatment in patients with EGFR mutation-positive non-small-cell lung cancer (KTORG1402). (September 2019)

5. A predictive model for carcinogenesis in patients with chronic hepatitis B undergoing entecavir therapy and its validation. Issue 36 (September 2016)

6. A predictive model for carcinogenesis in patients with chronic hepatitis B undergoing entecavir therapy and its validation. Issue 36 (September 2016)

7. A proposed predictive model for advanced fibrosis in patients with chronic hepatitis B and its validation. Issue 35 (August 2016)

8. A randomized phase II study of bevacizumab in combination with docetaxel or S-1 in patients with non-squamous non-small-cell lung cancer previously treated with platinum based chemotherapy (HANSHIN Oncology Group 0110). Issue 2 (August 2015)

9. A randomized phase II study of docetaxel or pemetrexed with or without the continuation of gefitinib after disease progression in elderly patients with non‐small cell lung cancer harboring EGFR mutations (JMTO LC12‐01). Issue 12 (13th May 2022)